magnetic jewelry wholesaler - online magnetic jewelry

A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients with hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people.

“The high CD4/CD8 ratio and suppressed NK cell activity were improved by methyl-B12 treatment.” The Japanese researchers state: “We conclude that vitamin B12 acts as an immunomodulator for cellular immunity.”11 B12 was used successfully in the treatment of IgE-mediated skin disorders. The German researchers conclude that B12 (cobalamin) when applied to the skin one or more times per day exhibited “...excellent results in topical treatment of skin disorders and in particular of inflammatory and hyperproliferative skin ailments and/or cutaneous manifestations of illness which are immunologic in origin, e.g. psoriasis, atopic dermatitis, contact dermatitis, magnetic and other eczematous dermatitises...”12 Click here for Allergy medication online.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points jewelry of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg wholesaler of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6